However, although it has been proved that VEGF plays an indispensable role in tumor angiogenesis mediated by RAS, seldom do we have studies involving the relationship between KRAS mutations and antiangiogenic therapy efficacy (70–72). This evidence concerns the gene KRAS and neoplasm.